Myriad Genetics (MYGN) Receivables - Other (2009 - 2021)

Myriad Genetics (MYGN) has reported Receivables - Other for 13 consecutive years, with -$700000.0 the latest figure, recorded in Q2 2021.

• In Q2 2021, Receivables - Other rose 22.22% year-over-year to -$700000.0; the TTM figure through Jun 2021 stood at $1.7 million (down 46.88% YoY), while the FY2020 annual figure was $2.0 million, changed N/A from the prior year.
• Receivables - Other retreated to -$700000.0 in Q2 2021 per MYGN's latest filing, from $2.4 million in the prior quarter.
• Across five years, Receivables - Other topped out at $6.9 million in Q3 2017 and bottomed at -$900000.0 in Q2 2020.
• Historically, Receivables - Other has averaged $3.0 million across 5 years, with a median of $3.2 million in 2018.
• Annual changes were most pronounced in 2017 — Receivables - Other jumped 900.0% — and 2020, when it slumped 400.0%.
• Myriad Genetics' Receivables - Other stood at $6.0 million in 2017, then fell by 1.67% to $5.9 million in 2018, then sank by 40.68% to $3.5 million in 2019, then plunged by 42.86% to $2.0 million in 2020, then tumbled by 135.0% to -$700000.0 in 2021.
• Business Quant data shows MYGN's Receivables - Other at -$700000.0 in Q2 2021, $2.4 million in Q1 2021, and $2.0 million in Q4 2020.